Researchers determined the effect of prenatal and early postnatal lead exposure on risk for depression and anxiety in adulthood.

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

People with major depressive disorder or schizophrenia have been found to have lower levels of the synaptic protein "SNAP-25" ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Mental disorders that cause physical symptoms are not included in a major health trends study, despite them impacting as many as 1 in 21 adults, researchers have found. Somatoform disorders could be ...

Mental disorders that cause physical symptoms are not included in a major health trends study, despite them impacting as many ...

Is long-term psychotherapy more effective for complex conditions? In my case it was. Working with a psychiatrist for 11 years ...

Scientists have developed a portable biosensor that can detect levels of BDNF, a protein linked to mental health conditions ...